Ton Coolen
Ton Coolen

Saddle Point Science Europe: Turning Theory into Impact

A cancer therapy that is rejected because its overall benefit is too low rarely gets a second look. Yet when Saddle Point Science Europe reanalysed the data with modern statistical methods, something striking emerged: around 10% of patients had lived, on average, a full year longer thanks to the treatment, and these could be identified beforehand.

Traditional standard models had been unable to do this. For Saddle Point, it’s a clear example of how modern analytical methods can reveal opportunities for personalised medicine that would otherwise remain invisible. According to the founder of Saddle Point, Ton Coolen, this is not due to the unwillingness but to the nature of the field. Medical statistics is conservative, and new approaches take time to be accepted. 

Coolen, also professor at the Donders Institute, illustrates the limitations of traditional models with a simple comparison: “looking at Saturn through binoculars, makes it look like a blob. But if you build a telescope, suddenly you see the rings.” Saddle Point aims to do the same for medical data: uncover hidden structures that enable treatment to be matched to the patients most likely to benefit. In other words, taking a step towards personalised medicine.

To benefit medical scientists and patients

In cancer research, Coolen observed many clinicians working with analytical tools never designed for today’s complex, heterogenous data: “We want medical scientists to benefit from advanced mathematics without needing to become programmers,” Coolen explains. Alongside its software, the company also serves as data-analysis partner in international biomedical consortia, tackling problems that standard methods cannot address reliably.

The Launch as a catalyst

Saddle Point’s growth accelerated when the company joined The Launch. Being located on campus in Nijmegen enabled close collaboration between academics and spinout teams. The entrepreneurial environment was equally valuable; working alongside other start-ups and receiving practical guidance, from regional funding advice to introductions in the health-tech network, helped the company find its footing after relocating to the Netherlands.

Scaling impact

Saddle Point is now transitioning from EU-funded research collaborations to broader commercial adoption, particularly in the pharmaceutical sector. Their first major pharma client, GSK, is already on board. “The more widely our methods are used, the more impact we can make,” Coolen says. And that, ultimately, is the thread running through his work: moving from one size fits all statistics to data driven precision and personalisation.

From idea to impact: The Launch

Francien Mels supports Donders Institute researchers in taking their ideas beyond academia. She serves as the central contact for 
researchers who want to explore how they can translate their research into societal impact. Working from The Launch and the Knowledge Transfer Office, she helps researchers to think about societal impact from the earliest stages. 

As she puts it: “Even before a concrete idea emerges, we can already think along with researchers about how to connect their work to society. Depending on where researchers are in the process, there are different ways we can support them. For example, researchers who want to make societal impact but don’t know where to start can join the Societal Impact Workshop, while those who already have an idea can explore its potential through the Discovery Track” 

Her guidance spans the full journey, from shaping a concept and connecting with relevant partners to reviewing a business plan and securing initial funding. After that, startups such as Saddle Point can continue to grow, even finding housing within The Launch. 

For Mels, valorisation is an essential part of the research and she warmly invites colleagues to reach out, join the Societal Impact Workshop or Discovery Track, or simply drop by The Launch in the Forum building.

Francien Mels